申请人:Orion-yhtyma Oy
公开号:US05356923A1
公开(公告)日:1994-10-18
##STR1## Substituted cyclic hydroxamic acids of general formula (I) in which R.sub.1, R.sub.2 and R.sub.3 are independently hydrogen, halogen, lower alkyl, lower alkoxy, cycloalkoxy, aryloxy which is optionally substituted by 1 to 3 halogen, or aralkyloxy, which is optionally substituted by 1 to 3 halogen, or R.sub.1 and R.sub.2 together form a --O--CH.sub.2 --O-- group; with the proviso that R.sub.3 is not hydrogen when R.sub.1 and R.sub.2 are both hydrogen; R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl, R.sub.6 is hydrogen or lower alkyl and physiologically acceptable salts and esters thereof are selective inhibitors of phosphodiesterase IV activity and leukotriene B.sub.4 and C.sub.4 synthesis without showing any significant effect on phosphodiesterase III activity, and are therefore useful in the treatment of hypersensitivity and inflammatory diseases.
通式(I)中的取代环状羟肟酸,其中R.sub.1、R.sub.2和R.sub.3独立地表示氢、卤素、低烷基、低烷氧基、环烷氧基、取代1至3个卤素的芳氧基,或取代1至3个卤素的芳基烷氧基,或R.sub.1和R.sub.2共同形成--O--CH.sub.2--O--基团;在R.sub.1和R.sub.2均为氢时,R.sub.3不表示氢;R.sub.4和R.sub.5独立地表示氢或低烷基,R.sub.6表示氢或低烷基,其生理上可接受的盐和酯是磷酸二酯酶IV活性和白三烯B.sub.4和C.sub.4合成的选择性抑制剂,而不对磷酸二酯酶III活性显示任何显著影响,因此在治疗过敏和炎症性疾病方面有用。